Capricor Therapeutics, Inc. (CAPR)
Stock Price:
$4.03 USD
0.00 (0.00%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $4.06 +0.03 (0.74%) Nov 25, 7:59 PM
Key Info
| Market Cap |
82.40M |
| Revenue (ttm) |
474,520 |
| Net Income (ttm) |
-10.95M |
| Shares Out |
20.45M |
| EPS (ttm) |
-0.95 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 25 |
| Last Price |
$4.03 |
| Previous Close |
$4.03 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
4.00 |
| Day's Range |
3.87 - 4.13 |
| Day's Volume |
497,313 |
| 52-Week Range |
0.88 - 12.32 |
More Stats
| Market Cap |
82.40M |
| Enterprise Value |
47.42M |
| Earnings Date (est) |
Mar 17, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
20.45M |
| Float |
19.91M |
| EPS (basic) |
-1.03 |
| EPS (diluted) |
-0.95 |
| FCF / Share |
-0.42 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.19M |
| Short Ratio |
2.48 |
| Short % of Float |
5.98% |
| Beta |
7.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
173.66 |
| PB Ratio |
2.89 |
| Revenue |
474,520 |
| Operating Income |
-10.99M |
| Net Income |
-10.95M |
| Free Cash Flow |
-8.26M |
| Net Cash |
34.98M |
| Net Cash / Share |
1.71 |
| Gross Margin |
-871.78% |
| Operating Margin |
-2,316.61% |
| Profit Margin |
-2,307.30% |
| FCF Margin |
-1,740.06% |
| ROA |
-31.16% |
| ROE |
-64.44% |
| ROIC |
-1,030.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
12.0
Current: $4.03
High
12.0
Target: 12.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 1.01 | 1.67 | 2.67 | 4.00 | 5.52 | 4.79 | 0.50 | 1.90 | 1.35 | - |
| Revenue Growth | -39.87% | -37.32% | -33.32% | -27.53% | 15.27% | 851.19% | -73.5% | 40.18% | - | - |
| Gross Profit | 1.01 | 1.67 | 2.67 | 4.00 | 5.52 | 4.79 | 0.50 | 1.90 | 1.35 | - |
| Operating Income | -7.73 | -15.33 | -12.86 | -16.98 | -12.61 | -6.02 | -6.90 | -2.10 | -4.90 | -6.29 |
| Net Income | -7.64 | -15.19 | 2.43 | -18.81 | -12.86 | -6.22 | -8.89 | -2.07 | -4.88 | -6.03 |
| Shares Outstanding | 3.71 | 2.94 | 2.32 | 1.86 | 1.59 | 1.17 | 1.05 | 0.99 | 0.07 | 0.06 |
| Earnings Per Share | -2.06 | -5.17 | 0.90 | -10.10 | -8.10 | -5.30 | -8.50 | -2.10 | -65.00 | -95.00 |
| Operating Cash Flow | -6.82 | -13.86 | -14.23 | -14.45 | -10.82 | 0.96 | -6.14 | -2.06 | -4.65 | -4.32 |
| Capital Expenditures | - | -0.32 | -0.03 | -0.19 | -0.15 | -0.19 | -0.06 | -0.01 | - | - |
| Free Cash Flow | -6.82 | -14.18 | -14.26 | -14.65 | -10.97 | 0.77 | -6.20 | -2.08 | -4.65 | -4.32 |
| Cash & Equivalents | 9.89 | 7.54 | 14.87 | 17.54 | 13.57 | 11.01 | 3.46 | 4.38 | 1.09 | 3.38 |
| Total Debt | - | - | - | 13.91 | 9.16 | 9.16 | 3.96 | - | - | - |
| Net Cash / Debt | 9.89 | 7.54 | 14.87 | 3.64 | 4.41 | 1.86 | -0.50 | 4.38 | 1.09 | 3.38 |
| Assets | 11.11 | 9.25 | 16.27 | 18.75 | 16.07 | 13.63 | 5.54 | 5.42 | 1.37 | 3.67 |
| Liabilities | 4.27 | 4.63 | 5.05 | 22.75 | 17.10 | 19.88 | 6.07 | 0.53 | 0.54 | 1.07 |
| Book Value | 6.84 | 4.62 | 11.23 | -4.00 | -1.03 | -6.25 | -0.53 | 4.89 | 0.83 | 2.60 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Capricor Therapeutics, Inc. |
| Country |
United States |
| Employees |
16 |
| CEO |
Linda Marbán |
Stock Information
| Ticker Symbol |
CAPR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CAPR |
Description
Capricor Therapeutics, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.